

FINAL NARRATIVE REPORT

Principal Investigator:
Haesun A. Kim
Department of Biological Sciences
Rutgers University

Grant title: Functional analysis of erbB2 signaling during myelination
Grant number: 06-3059-SCR-E-O
Grant period: 06/15/2006 - 06/30/2010

Date of submission of the report: August 10, 2010

RECEIVED

AUG 12 2010

NJ COMMISSION ON
SPINAL CORD RESEARCH

1. Original aims of the project



The objective of study was to determine the therapeutic potential of Neuregulin (Nrg1)-erbB signaling in promoting remyelination on adult regenerating axons. Specifically, our study focused on investigating the role of Nrg1 on Schwann cell myelination as Schwann cell transplantation strategy has been shown to provide therapeutic benefit in promoting remyelination of injured axons in the CNS. For the study, we had the following three specific aims: 1) determine the Nrg1-erbB signaling mechanism that promotes Schwann cell myelination, 2) determine the effects of ectopic Nrg1-erbB signaling on Schwann cell myelination and 3) determine whether ectopic Nrg1-erbB signaling could improve myelination on adult regenerating axons.

2. Project successes

During the project period, we published four papers supported by the NJCSCR grant and presented our results at scientific meetings such as the annual meetings for the Society of Neuroscience, the American Society for Neurochemistry and the Gordon Research Conference. Below, I have summarized some of the significant findings from our studies.

a. Ectopic stimulation of Schwann cells with soluble Nrg1 promote myelination and myelin maturation: To determine whether ectopic addition of Nrg1 improves Schwann cell myelination, we used an in vitro myelinating culture system in which isolated Schwann cells were co-cultured with dorsal root ganglion neurons. Cultures were treated with different doses of Nrg1 and myelination was assessed. As shown in Figure 1, the results show that stimulation with soluble Nrg1 not only increases the number of myelin segments formed on axons but also promote myelin maturation by increasing the myelin segmental lengths.

b. Soluble Nrg1 functions during the early stages of myelination following establishment of axon-Schwann cell association: Previous studies have shown that neuronal Nrg1 expressed on axonal membrane is required for Schwann cell-axon association and the subsequent myelination. To determine whether soluble Nrg1 could replace the role of axonal Nrg1, we co-cultured Schwann cells with neurons prepared from Nrg1^{+/-} and Nrg1^{-/-} mice and treated with soluble Nrg1. The data show that while soluble Nrg1 rescues myelination defects on Nrg1^{+/-} neurons (few myelin segments and short



internodal length) (Figure 2 A and B), it fails to rescue myelination in *Nrg1*^{-/-} neurons (not shown). Since Schwann cells associate normally on *Nrg1*^{+/-} axons but not on *Nrg1*^{-/-} axons, the result suggests that soluble *Nrg1* promotes stages of myelination subsequent to axon-Schwann cell association.

c. The pro-myelinating function of soluble Nrg1 is mediated by an increase in the PI3-kinase activation and Krox 20 expression. To define the signaling function of soluble *Nrg1*, we assessed various signaling pathways that are activated in Schwann cells upon soluble *Nrg1* treatment. We show that the pro-myelinating function of *Nrg1* is mediated by an increase in the PI3-kinase activation and expression of myelin proteins and *Krox 20*, a transcription factor required for myelination (Figure 2 C and D).



d. Soluble Nrg1 elicits a concentration-dependent, biphasic effect on Schwann cell myelination: A surprising finding of our study was the dose-dependent effect of soluble *Nrg1* that promotes or inhibits myelination. While soluble *Nrg1* promotes myelination at relatively low doses, it inhibits myelination at high doses in a manner that is dependent on *Mek1/2* activation: pharmacologic inhibitor to *Mek1/2* blocked the inhibitory effect of *Nrg1* (Figure 3). Furthermore, inhibition of the endogenous *Mek1/2* activity in co-cultures promoted myelination, indicating that activation of the *Ras/Raf/Erk* pathway functions as a negative signal for myelination (not shown).

e. Soluble Nrg1 is sufficient to induce myelination on normally non-myelinated axons: Small diameter axons, such as the ones of sympathetic neurons do not become myelinated, but ensheathed by the Schwann cells. The neurons express low levels of the membrane-bound *Nrg1*, insufficient for myelination. We show that ectopic stimulation of Schwann cells with soluble *Nrg1* induces myelination on sympathetic neurons (data not shown), demonstrating the pro-myelinating role of the *Nrg1*.

f. Adult axons express low levels of the membrane-bound Nrg1: Since regenerating axons in adult animals are often poorly myelinated, we speculated that adult axons do not express sufficient levels of *Nrg1* required for myelination. We prepared neurons from adult and embryonic dorsal root ganglion and compared the levels of the membrane-bound *Nrg1*. As shown in Figure 4 adult neurons expressed a significantly lower level of *Nrg1* compared to embryonic neurons. Based on our results above, we speculate that a therapeutic strategy using soluble *Nrg1* may improve remyelination on injured adult axons.

3. Project challenges

In our original aims we had proposed to generate both loss-of-function and gain-of-function phenotypes for *erbB2*, a receptor for *Nrg1*, to investigate the role of *Nrg1-erbB* signaling during



Schwann cell myelination and to determine whether increasing the erbB2 activity would promote remyelination. Modulating the erbB expression in Schwann cells or knocking-down erbB activity by expressing dominant negative mutant was proven to be difficult. As an alternative approach, we investigated the effect of the ligand, Nrg1 and generated a gain-of-function (ectopic stimulation with soluble Nrg1) and a loss-of-function (use of Nrg1-deficient neurons) phenotypes and successfully completed most of the aims of the proposed study.

4. Implications for future research and/or clinical treatment

Rebuilding of myelin in demyelinated lesions in the CNS by transplanting exogenous myelin-forming glial cells is a concept that has been explored and tested for many years. Schwann cells offer the possibility of autologous transplantation as they are easily obtained and expanded in culture, and myelinate when transplanted in demyelinated lesions. However Schwann cell remyelination of adult axons is often incomplete, resulting in the formation of thinner myelin sheathes and shorter internode compared to normal nerves. The pro-myelinating effect of soluble Nrg1 presented in this study is significant as it provides a potential therapeutic strategy for improving myelination by Schwann cells. However, it should be cautioned that concentrations above the threshold level could have a devastating consequence on the pathologic condition. Further understanding of the inhibitory role of Ras/Raf/Erk pathway on myelination might provide insights into developing a combined strategy for improving myelination.

5. Plans to continue this research, including applications submitted to other sources for ongoing support

To investigate the therapeutic potential of soluble Nrg1 to improve remyelination on adult axons, we will further define the Nrg1-signaling property of adult axons to determine whether there is a deficiency in activating crucial pro-myelinating signals in the associated Schwann cells. We will also determine whether soluble Nrg1 improves myelination on adult axons by increasing the pro-myelinating signal. Lastly, we will determine the effect of soluble Nrg1 on remyelination in vivo. A grant proposal is in preparation to be submitted to NIH. We have also begun to investigate molecular mechanisms regulating oligodendrocyte myelination using in vitro myelinating co-culture system.

6. List of publications

1. Syed, N. and H. A. Kim. Soluble neuregulin and Schwann cell myelination: A therapeutic potential for improving remyelination of adult axons. *Submitted to Molecular Cellular Pharmacology*
2. Syed, N., K. Reddy, D. P. Yang, C. Taveggia, J. L. Salzer, P. Maurel, and H. A. Kim. Soluble neuregulin-1 has bi-functional, concentration-dependent effects on Schwann cell myelination *Journal of Neuroscience* 2010 30: 6122-6131
3. Yang, D. P., D. P. Zhang, K. S. Mak, D. E. Bonder, S. L. Pomeroy and H. A. Kim. Schwann cell proliferation during Wallerian degeneration is not necessary for regeneration and remyelination of the peripheral nerves: axon-dependent removal of newly generated Schwann cells by apoptosis. *Molecular and Cellular Neuroscience*, 2008 38(1): p. 80-88